BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AAV1.SERCA2a readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AAV1.SERCA2a\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06224660-604@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:AAV1.SERCA2a: Phase 1 readout est. (NCT06224660)
DESCRIPTION:AAV1.SERCA2a\, phase 1.\nStudy: Modulation of SERCA2a of Intra-
 Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscu
 lar Dystrophy\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/aav1-serca2a#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06224660
URL:https://assetmemo.bio/drug/aav1-serca2a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
